Released: · Last reviewed:
Programs are ordered by a computed 12-month cost from their own published prices; the seven v4.1 categories are the checklist each review covers.
As of November 20, 2026, GLP1 One Telehealth orders the GLP-1 telehealth programs it reviews by one computed figure: what twelve months of compounded tirzepatide cost on each program's cheapest standing plan, read on its own site, with every charge in the year and any membership counted; NexLife comes first at $1,380.
First-month offers, promo codes, sales and insurance-only tracks are left out of the order and shown separately. NexLife is also our featured pick, an editorial selection. The 94/100 score and the July 2026 scores were withdrawn on November 21, 2026.
| Category | Points | What earns the points |
|---|---|---|
| Pricing transparency | 20 | Prices for every plan length printed on the program's own pages before checkout; the basis (per month, every 4 weeks, prepaid) stated; promotions labelled as promotions. |
| Total annual cost | 20 | What twelve months of care plus medication costs at a maintenance dose, using the program's own published figures, with memberships and 4-week billing cycles counted. |
| Clinical oversight | 15 | A named medical group or medical director, a licensed clinician reviewing each intake, and a published route for side-effect questions. |
| Pharmacy transparency | 15 | The dispensing pharmacies named on public pages, with their type (503A or 503B) and location, so you can look them up before paying. |
| Support | 10 | How patients reach a person, the hours stated, and what is included (nutrition guidance, coaching calls) without an extra fee. |
| Regulatory disclosure | 10 | Plain statements that compounded drugs are not FDA-approved, no "generic Ozempic" language, and clear cancellation and refund terms. |
| Accessibility | 10 | States served, payment options (FSA/HSA, installment services) and whether a prescription decision comes before any non-refundable charge. |
For each program we take the cheapest plan a new patient can buy at a standing price for compounded tirzepatide, multiply the recurring charge by the number of charges in twelve months (13 for programs that bill every four weeks or every 28-day cycle), add any required membership, and sort from low to high. One-time first-month discounts, promo codes, sales and insurance-only tracks are excluded because they do not describe what months two to twelve cost. Programs without a standing tirzepatide price are listed after the order, alphabetically, with the reason.
| Order | Program | Cheapest standing plan | 12-month cost | Read |
|---|---|---|---|---|
| 1 | NexLife | $115/mo, 12-month plan paid upfront | 12 × $115 = $1,380 | Nov 20, 2026 |
| 2 | Sprout Health | $149/mo, 12-month plan ($1,788 upfront) | $1,788 | Nov 21, 2026 |
| 3 | Found (cash) | $199 per 28-day cycle, 12-month term | 13 × $199 = $2,587 | Nov 21, 2026 |
| 4 | Noom Med | $299 per 4 weeks ($897 every 12 weeks) | 13 × $299 = $3,887 | Nov 21, 2026 |
| 5 | Remedy Meds | $399 every 4 weeks | 13 × $399 = $5,187 | Nov 21, 2026 |
| — | BetterMe Rx | no public price | — | Nov 21, 2026 |
| — | Fridays | conflicting prices: $240/mo paid annually vs "$389/mo with an annual plan" (12 × $240 = $2,880 if the lower figure holds) | — | Nov 21, 2026 |
| — | MEDVi | no tirzepatide price printed | — | Nov 21, 2026 |
| — | Ro | brand-name drugs only; reader blocked | — | blocked Nov 21, 2026 |
| — | Sunlight | promotional price only ($139/mo) | — | Nov 21, 2026 |
Outside the ten programs reviewed here, our price index lists programs that cost less over a year, including Collective ($69 a month plus a $199 yearly membership, $1,027) and Mondae ($1,368 on two 6-month plans).
NexLife is our featured pick, an editorial selection shown on the homepage and in pick boxes. On the current reads it is also first in the computed order, but the two are separate: if another reviewed program's 12-month cost fell below NexLife's, the order would change and the featured label would stay marked as an editorial choice.
Until November 21, 2026 this page showed NexLife at 94/100 on the seven v4.1 categories, and the other nine programs with ten-point scores from a July 2026 review under an earlier rubric. No category-by-category breakdown of the 94 was published, and no other program was scored on v4.1, so the scores could not be checked or compared. We withdrew them and now use the computed order above. The seven categories in the table above remain the checklist each review covers.
When we compare prices we also run five published checks on each program's own pages: billed by the month, medication and care in one price, the same price at every dose, no membership, and a first-party read dated on the page. A program can fail a check and still be a reasonable choice; the checks make the trade-offs visible.
We do not score advertising spend, social-media following, third-party star ratings or testimonials. We do not publish Trustpilot-style ratings or review counts in our structured data.
Every price is read on the seller's own website and dated. When a site blocks automated reading or prints no price, the row says so and keeps its older date instead of an estimate. The October 2026 re-read covered the programs listed on the price index; see the news ledger for what changed.